A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

Dr. William Russell specializes in radiation oncology in Baton Rouge. He graduated from the University of Mississippi School of Medicine in 1984. Russell is double-board certified in internal medicine ...

Men treated for nonmetastatic prostate cancer under current guidelines are up to 6 times less likely to die from their cancer than from other causes, according to data from a Swedish cancer registry.

Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...

National guidelines from associations such as the National Comprehensive Cancer Network (NCCN) and the American Urological Association recommend that men with a life expectancy of less than 10 years ...

What are the current prostate cancer screening guidelines and treatment recommendations? Men may be offered prostate cancer screening at different life stages depending on their individual risk. Age, ...